SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddys Laboratories informs about disclosure

17 May 2025 Evaluate
Dr Reddys Laboratories has informed that the United States Food & Drug Administration (USFDA) completed a GMP inspection at its API Middleburgh facility in New York. The inspection was conducted from 12th May, 2025 to 16th May, 2025 (US EST time). They have been issued a Form 483 with 2 observations, which they will address within the stipulated timeline. 

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Labs. Share Price

1245.50 -24.30 (-1.91%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: